BackRevolution Medicines Overview

Revolution Medicines Total Current Liabilities

Latest total current liabilities for RVMD: $290M.

Get informed when a big investor buys or sells

+ Follow
Total Current Liabilities
$289.60M
82.60% YoYΔ $131.00M vs prior year quarter

Peer average

Loading

Revolution Medicines Total Current Liabilities History

Loading

Revolution Medicines vs. peers: Total Current Liabilities Comparison

Loading

Revolution Medicines Total Current Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Revolution Medicines (RVMD) FAQ

As of the most recent data (March 2026), RVMD shows a total current liabilities of $290M. That compares with $160M in the prior-year period — up 82.6% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, RVMD's total current liabilities is now $290M (was $160M) — a 82.6% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Revolution Medicines is outperforming or lagging.

Tracking RVMD's total current liabilities over time shows whether Revolution Medicines is scaling, shrinking, or reshaping that part of the business. The current reading is $290M That compares with $160M in the prior-year period — up 82.6% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this total current liabilities page, Stockcircle has Revolution Medicines's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect total current liabilities (currently $290M) with ownership activity and broader fundamentals.

Revolution Medicines's total current liabilities is $290M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.